Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023
Settlement and Product Sales Drive Esperion's Financial Performance
Sheldon Koenig Esperion Therapeutics Inc Financial Performance Cost Savings Revenue Growth Litigation Settlement
Source: yahoo.com